Baseline patient characteristics among all three adjuvant NY-ESO-1 clinical trials
| NCT00821652 | NCT01079741 | NCT00124124 | ||
|---|---|---|---|---|
| N = 22 | N = 35 | N = 34 | ||
| N(%)/Mean(SD) | N(%)/Mean(SD) | N(%)/Mean(SD) | P-Value | |
| Age | 59.68 (13.60) | 55.49 (15.16) | 56.38 (11.82) | 0.5134 |
| Sex | 0.2446 | |||
| Female | 9 (40.91) | 14 (40.00) | 20 (58.82) | |
| Male | 13 (59.09) | 21 (60.00) | 14 (41.18) | |
| Thicknessa | 2.63 (1.64) | 2.22 (1.84) | 4.48 (5.63) | 0.0122 |
| Ulceration | 0.1916 | |||
| Present | 7 (31.82) | 11 (31.43) | 18 (52.94) | |
| Absent | 10 (45.45) | 17 (48.57) | 14 (41.18) | |
| Undetermined | 5 (22.73) | 7 (20.00) | 2 (5.88) | |
| AJCC Stage | 0.0146 | |||
| IIB | 0 (0.00) | 3 (8.57) | 7 (20.59) | |
| IIC | 1 (4.55) | 1 (2.86) | 0 (0.00) | |
| IIIA | 5 (22.73) | 4 (11.43) | 6 (17.65) | |
| IIIB | 5 (22.73) | 11 (31.43) | 10 (29.41) | |
| IIIC | 4 (18.18) | 12 (34.29) | 10 (29.41) | |
| IV | 7 (31.82) | 4 (11.43) | 0 (0.00) | |
| Undetermined | 0 (0.00) | 0 (0.00) | 1 (2.94) | |
| Histologic Subtype | 0.5588 | |||
| Nodular | 6 (27.27) | 7 (20.00) | 12 (35.29) | |
| Superficial Spreading | 4 (18.18) | 5 (14.29) | 7 (20.59) | |
| Other | 3 (13.64) | 2 (5.71) | 4 (11.76) | |
| Undetermined | 9 (40.91) | 21 (60.00) | 11 (32.35) | |
| Primary site | 0.2624 | |||
| Anterior Trunk | 0 (0.00) | 4 (11.43) | 6 (17.65) | |
| Arms | 3 (13.64) | 5 (14.29) | 1 (2.94) | |
| Head/Neck | 5 (22.73) | 3 (8.57) | 6 (17.65) | |
| Legs | 8 (36.36) | 15 (42.86) | 12 (35.29) | |
| Posterior Trunk | 3 (13.64) | 6 (17.14) | 8 (23.53) | |
| Unknown | 3 (13.64) | 2 (5.71) | 1 (2.94) |
amissing values for thickness: NCT00821652: 4; NCT01079741: 5;NCT00124124: 1